| 書目名稱 | Drugs for HER-2-positive Breast Cancer |
| 編輯 | Maria Sibilia,Christoph C. Zielinski,Thomas W. Gru |
| 視頻video | http://file.papertrans.cn/284/283218/283218.mp4 |
| 概述 | Contemporary monograph on the treatment of breast cancer.-.Gives a comprehensive account of drugs for HER2-positive breast cancer.-.A valuable source of information for researchers and clinicians from |
| 叢書名稱 | Milestones in Drug Therapy |
| 圖書封面 |  |
| 描述 | .Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.. |
| 出版日期 | Book 2011 |
| 關(guān)鍵詞 | HER-2-positive Breast Cancer; Pertuzumab; Second Generation targeted Therapies; Trastuzumab; antibodies |
| 版次 | 1 |
| doi | https://doi.org/10.1007/978-3-0346-0094-1 |
| isbn_softcover | 978-3-0348-0318-2 |
| isbn_ebook | 978-3-0346-0094-1Series ISSN 2296-6056 Series E-ISSN 2296-6064 |
| issn_series | 2296-6056 |
| copyright | Springer Basel AG 2011 |
|Archiver|手機版|小黑屋|
派博傳思國際
( 京公網(wǎng)安備110108008328)
GMT+8, 2025-10-31 05:35
發(fā)表于 2025-3-21 18:34:14
